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CHD4 regulates the DNA damage 
response and RAD51 expression in 
glioblastoma
Lisa D. McKenzie  1, John W. LeClair1, Kayla N. Miller1, Averey D. Strong1, Hilda L. Chan1, 
Edward L. Oates1, Keith L. Ligon2, Cameron W. Brennan3 & Milan G. Chheda  1,4
Glioblastoma (GBM) is a lethal brain tumour. Despite therapy with surgery, radiation, and alkylating 
chemotherapy, most people have recurrence within 6 months and die within 2 years. A major reason 
for recurrence is resistance to DNA damage. Here, we demonstrate that CHD4, an ATPase and 
member of the nucleosome remodelling and deactetylase (NuRD) complex, drives a component of this 
resistance. CHD4 is overexpressed in GBM specimens and cell lines. Based on The Cancer Genome Atlas 
and Rembrandt datasets, CHD4 expression is associated with poor prognosis in patients. While it has 
been known in other cancers that CHD4 goes to sites of DNA damage, we found CHD4 also regulates 
expression of RAD51, an essential component of the homologous recombination machinery, which 
repairs DNA damage. Correspondingly, CHD4 suppression results in defective DNA damage response 
in GBM cells. These findings demonstrate a mechanism by which CHD4 promotes GBM cell survival 
after DNA damaging treatments. Additionally, we found that CHD4 suppression, even in the absence 
of extrinsic treatment, cumulatively increases DNA damage. Lastly, we found that CHD4 is dispensable 
for normal human astrocyte survival. Since standard GBM treatments like radiation and temozolomide 
chemotherapy create DNA damage, these findings suggest an important resistance mechanism that 
has therapeutic implications.
Glioblastoma (GBM) is the most common and aggressive brain tumor1. Treatment is surgery, radiation and the 
alkylating chemotherapy, temozolomide. After treatment, tumour recurrence is almost inevitable and on average 
occurs within 6 months2,3. Most patients die within 2 years4. Here, we have focused on a potential way to improve 
DNA damaging therapies by targeting chromodomain helicase DNA binding protein 4 (CHD4).
CHD4 is a highly conserved protein that is the core ATPase subunit of the nucleosome remodelling and 
deacetylase (NuRD) complex5. NuRD transcriptionally represses and activates genes6, arrests cell cycle pro-
gression at the G1/S transition7,8, and facilitates lineage commitment during embryonic development9,10. The 
NuRD complex can either promote or suppress tumourigenesis, depending on the context11. However, we 
know less about the role of CHD4 in cancer. Recent studies suggest CHD4 has several potential oncogenic and 
resistance-driving activities in multiple cell types. For example, somatic mutations in the CHD4 gene occur 
in approximately 20% of serous endometrial cancers, over half of which are located in its ATPase domain12. 
Overexpression of CHD4 is also associated with poor prognosis in non small-cell lung cancer (NSCLC)13, hepa-
tocellular carcinoma (HCC)14 and colorectal cancer15. In colorectal cancer, CHD4 promotes the recruitment of 
DNA methyltransferases to tumour suppressor gene promoters, thereby repressing their expression and promot-
ing tumourigenesis15. We previously found CHD4 is required to maintain GBM tumour initiating cell morphol-
ogy and stem cell marker expression16. Therefore, CHD4 can promote cancer in multiple cell types.
CHD4 plays important roles in genome integrity by regulating signalling and repair after DNA damage11,17–20. 
In response to ionizing radiation or oxidative stress, CHD4 and the NuRD complex are rapidly recruited to sites 
of DNA damage through CHD4 association with Poly(ADP-ribose) polymerase 1 (PARP1). There, CHD4 helps 
create a repressive chromatin structure to prevent transcription of damaged genes15,18. Outside of its interaction 
with NuRD members, CHD4 is also recruited to the sites of DNA damage by RING finger ubiquitin ligase 8 
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(RNF8), which promotes assembly of DNA repair factors such as RNF168 and BRCA119. Lastly, in response to 
DNA damage, the DNA damage response (DDR) kinases ATM21 and ATR22 phosphorylate CHD4. In turn, CHD4 
also phosphorylates ATM in response to DNA damage23. Thus, CHD4 may be required for DNA repair and cell 
survival through multiple mechanisms.
CHD4 expression also promotes resistance to chemotherapeutic agents in some cancers. CHD4 contrib-
utes to cisplatin resistance in BRCA2-mutant breast cancers, by acting in an homologous recombination 
(HR)-independent manner24. In addition, CHD4 depletion in acute myeloid leukaemia (AML) cell lines increases 
sensitivity to cytarabine and daunorubicin23. These treatment resistance mechanisms are related to the role of 
CHD4 in DNA damage repair. However, given the multifaceted roles of CHD4, it is also likely that whether or not 
it drives resistance, and how it does this, is highly context dependent. We set out to explore the relevance of CHD4 
to DNA damage response in GBM since DNA damage with radiation and alkylating chemotherapy has been the 
backbone of GBM treatment for decades.
Here, we report that CHD4 is overexpressed in GBM patient samples and cell lines, and that high expression 
of CHD4 correlates with poorer survival. We also demonstrate that survival of GBM cells, but not normal human 
astrocytes, depends upon CHD4. We provide evidence that CHD4 depletion causes DNA damage in GBM cell 
lines, even in the absence of exogenous DNA damaging agents, and that this may be due to decreased expres-
sion of RAD51. Finally, we show that CHD4 directly binds to the RAD51 promoter, and loss of CHD4 results in 
decreased activity at this promoter. Together, these data suggest a new manner by which CHD4 promotes the 
DDR response: through its direct regulation of RAD51. As such, CHD4 overexpression in GBM may promote cell 
survival and resistance to radiation, the mainstay of GBM treatment.
Results
CHD4 is highly expressed in GBM and is associated with poor patient survival. We analysed 
CHD4 mRNA expression data from The Cancer Genome Atlas (TCGA)25 and Rembrandt26 patient datasets 
using the GlioVis data portal27 to determine relative CHD4 expression in brain tumours. CHD4 mRNA is sig-
nificantly upregulated in GBM patients (n = 528) compared with non-tumour controls (n = 10) in the TCGA 
dataset (p = 2.2e-05) (Fig. 1a). Similarly, CHD4 mRNA expression is significantly upregulated in GBM (n = 219, 
p = 2.3e-14) compared with non-tumour patient samples (n = 28) in the Rembrandt dataset (Fig. 1b). We com-
pared CHD4 protein expression in multiple GBM cell lines (LN229, U251 and U87), tumour initiating cells 
(TS667, TS665 and BT112), and normal human astrocytes (NHA). Consistent with the patient data, CHD4 was 
more highly expressed in GBM cell lines compared with NHA (Fig. 1c). We then investigated whether high 
CHD4 expression correlates with poorer survival in patients by analysing patient survival data from the TCGA 
and Rembrandt datasets. We focused on the classical GBM subtype, because it is the most common type of GBM. 
Classical GBM patients in the TCGA dataset with CHD4 mRNA expression in the highest quartile (n = 50) have 
a significantly lower median survival (12.9 months) than patients with CHD4 mRNA expression in the lowest 
quartile (n = 51; 15.7 months), p = 0.0231 (Fig. 1d); these results did not change when we excluded patients with 
the glioma-CpG island methylator phenotype (G-CIMP) (n = 2). We found similar outcomes in the Rembrandt 
dataset, with classical GBM patients with high CHD4 expression (n = 16) having a significantly lower median 
survival (11.45 months) compared with classical subtype patients with low CHD4 mRNA expression (n = 16; 
20.4 months), p = 0.0079 (Fig. 1e). Together, these findings demonstrate that CHD4 is highly expressed in GBM 
compared with normal brain and that, within classical GBM, CHD4 expression is associated with poor survival. 
CHD4 expression was significantly higher to a similar degree in all subclasses of GBM. However, the association 
of high CHD4 expression and poor survival was only observed in the classical GBM subtype.
CHD4 is required for GBM cell viability. To test the effects of CHD4 on cell survival in GBM, we used 
multiple shRNAs targeting CHD4 in GBM cell lines (LN229 and U251) and NHAs. We focused on cell lines 
because tumour initiating cells differentiate after CHD4 suppression16, which confounds interpretation of pro-
liferation and viability effects outside a general state change effect. All three cell lines transduced with shRNAs 
expressed less CHD4 protein when compared with the non-targeting control (shCTRL) (Fig. 2a). While CHD4 
suppression mildly decreased NHA cell viability, it significantly decreased viability in LN229 and U251 cells 
(Fig. 2b). We then performed annexin V and propidium iodide (PI) staining followed by flow cytometry to deter-
mine whether this decreased cell number was due to increased apoptosis. We found that both shRNAs markedly 
increased the percentage of annexin V-positive LN229 and U251 cells (Fig. 2e–h). In contrast, CHD4 suppression 
had little effect on NHAs (Fig. 2c,d). These results demonstrate that GBM cell lines are more dependent on CHD4 
for survival than normal cells.
CHD4 is required for the GBM DNA damage response. Previous studies have shown that CHD4 has a 
role in the DNA damage response (DDR)8,11,17. We therefore investigated whether the increased cell death was a 
consequence of defective DDR. We found that even in the absence of external DNA damage, CHD4 suppression 
caused an increase in phosphorylated H2Ax (γH2Ax) in GBM cell lines (Fig. 3a,b) and tumour initiating cells 
(Supplementary Fig. 1), indicating an increase in DNA DSBs. To confirm that the observed results were not due 
to off-target effects of the shRNAs, we generated an shRNA-resistant CHD4 allele (CHD4RES). The resistant allele 
partially rescued CHD4 protein and γH2Ax levels (Fig. 4a), and partially rescued cell viability (Fig. 4b,c) and 
prevented apoptosis (Fig. 4d,e). To further investigate the role of CHD4 in the DDR in GBM cells, we exposed 
LN229 cells to radiation and observed elevated CHD4 expression within 1 hour (Fig. 3c). We also found that 
cell viability was significantly decreased in CHD4-suppressed LN229 cells after exposure to radiation, whereas 
control cell viability was not significantly changed (Fig. 3d), indicating that CHD4 suppression sensitises cells to 
radiation-induced DNA damage. Further, to assess the role of CHD4 in the setting of exogenous DNA damage, 
we measured γH2Ax levels over time after irradiation. As expected, control cells showed an initial increase in 
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γH2Ax, followed by resolution to endogenous levels by 2 hours after irradiation. CHD4-depleted LN229 cells did 
not show an increase in γH2Ax after irradiation (Fig. 3e) compared to the non-irradiated CHD4-depleted cells. 
This suggests that H2Ax is already maximally activated in cells lacking CHD4. We had similar results in tumour 
initiating cells. CHD4 suppression resulted in higher basal levels of γH2Ax and sustained γH2Ax after irradiation 
(Supplementary Fig. 1). These results indicate that under basal conditions, CHD4 is required for DSB repairs, and 
suggest that in the absence of CHD4, there is a deficit in repair and resolution of γH2Ax after radiation exposure.
Figure 1. CHD4 is overexpressed in GBM and is associated with worse survival. (a) CHD4 mRNA expression 
in non-tumour (n = 10) and GBM patient samples (n = 526) in The Cancer Genome Atlas (TCGA). p = 2.2e-05.  
(b) CHD4 mRNA expression in non-tumour (n = 28) and GBM (n = 219) patient samples in the NCI 
Rembrandt repository. p = 2.3e-14. (c) Immunoblot for CHD4 in normal human astrocytes (NHA) and GBM 
cell lines. Full-length blots are presented in Supplementary Fig. 3. (d,e) Kaplan-Meier survival curves of GBM 
(classical subtype) patients with low CHD4 mRNA expression (CHD4 Low) and high CHD4 mRNA expression 
(CHD4 High) from TCGA (p = 0.0231) (d) and the Rembrandt (p = 0.0079) (e) data. Data are shown as the 
mean ± SEM (a,b). Significance was analysed with pairwise t-test with Bonferroni correction (a,b) or log-rank 
test (d,e). *p ≤ 0.05; **p ≤ 0.001; ***p ≤ 0.0001.
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CHD4 positively regulates HR activity and RAD51 expression. To determine why CHD4 silencing 
resulted in increased γH2Ax in GBM cells, we measured homologous recombination (HR) efficiency after CHD4 
suppression. HR is a major DNA repair mechanism that is important in DSB repair. In comparison with the con-
trol, HR efficiency in cells with CHD4 suppression was significantly decreased (Fig. 5a). To further investigate 
this decreased HR efficiency, we measured RAD51 expression. RAD51 is an essential component of HR-mediated 
DNA damage repair; RAD51 promotes single strand invasion during HR28,29. RAD51 is overexpressed in multiple 
cancers, correlates with poor prognosis30, and is associated with radioresistance in GBM31. When we depleted 
CHD4, there was decreased RAD51 protein and mRNA in GBM cell lines (Fig. 5b,c) and tumour initiating 
cells (Supplementary Fig. 1). Since RAD51 expression is altered during different phases of the cell cycle32,33, we 
Figure 2. CHD4 suppression kills glioma cells but not normal astrocytes. (a) Immunoblot for CHD4 
expression after suppression with indicated shRNAs in normal human astrocytes (NHA), and glioma cell 
lines, LN229 and U251. Full-length blots are presented in Supplementary Fig. 3. (b) Relative cell number after 
CHD4 suppression, normalized to non-targeting control, at 5 days post-shRNA transduction (NHA: shCTRL 
vs. shCHD4 #1, p = 0.0706, shCTRL vs. shCHD4 #2, p = 0.0042; LN229: shCTRL vs. shCHD4 #1, p = 0.0003, 
shCTRL vs. shCHD4 #2, p < 0.0001; U251: shCTRL vs. shCHD4 #1, p = 0.0002, shCTRL vs. shCHD4 #2, 
p = < 0.0001). (c) AnnexinV and propidium iodide (PI) labelling of NHAs 5 days after shRNA transduction. (d) 
Quantification of Annexin V positive cells from (c) (shCTRL vs. shCHD4 #1, p = 0.0129, shCTRL vs. shCHD4 
#2, p = 0.076). (e) AnnexinV and PI labelling of LN229 cells 5 days after shRNA transduction (f) Quantification 
of Annexin V positive cells from (e) (shCTRL vs. shCHD4 #1, p < 0.0001, shCTRL vs. shCHD4 #2, p < 0.0001). 
(g) AnnexinV and PI labelling of U251 cells 5 days after shRNA transduction. (h) Quantification of Annexin 
V positive cells from (g) (shCTRL vs. shCHD4 #1, p < 0.0001, shCTRL vs. shCHD4 #2, p = 0.0003). Data are 
shown as mean ± SEM. ns = not significant; *p ≤ 0.05; **p ≤ 0.001; ***p ≤ 0.0001. All data is representative of 
three independent experiments (with three technical replicates each).
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Figure 3. CHD4 suppression causes increased γH2Ax, and prolongs time to repair after ionizing radiation (IR). 
(a) Immunoblot for γH2Ax after CHD4 suppression in LN229 and U251 cells. Full-length blots are presented 
in Supplementary Fig. 3. (b) Immunofluorescent staining of LN229 cells with DAPI (blue), γH2Ax (red), and 
combined after expression of shCTRL or shCHD4#1. (c) Immunoblot for CHD4 expression over time in LN229 
cells exposed to 9 Gy radiation. Full-length blots are presented in Supplementary Fig. 3. (d) Cell number of 
LN229 cells expressing shCTRL or shCHD4#1 3 days after exposure to either 0 Gy, 3 Gy, or 6 Gy radiation. Cell 
number is expressed as a percentage relative to 0 Gy (shCTRL cells: 0 Gy vs. 3 Gy, p = < 0.99999; 0 Gy vs. 6 Gy, 
p = 0.141; shCHD4#1 cells: 0 Gy vs. 3 Gy, p = 0.0144; 0 Gy vs. 6 Gy, p = 0.0001). (e) Immunoblots for γH2Ax 
in LN229 cells expressing shCTRL or shCHD4 #2 after either no radiation (0 Gy) or 1, 2, 4, 6 or 8 hours after 
exposure to 10 Gy radiation. The corresponding immunoblot for CHD4 expression after shCTRL or shCHD4#2 
is also shown. Full-length blots are presented in Supplementary Fig. 3. Data in (d) is shown as mean ± SEM; 
*p ≤ 0.05; ***p ≤ 0.0001. All data is representative of three independent experiments (with three technical 
replicates each).
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performed cell cycle analysis using PI staining and flow cytometry. We did not observe a significant change in cell 
cycle profile or increased p21 expression in either cell line (Supplementary Fig. 2), indicating that the decreased 
RAD51 expression is not a response to alterations in cell cycle phase. Therefore, these results demonstrate that 
CHD4 regulates RAD51 protein and mRNA expression in GBM cells.
CHD4 binds to the RAD51 promoter and promotes an active chromatin state. CHD4 is a mem-
ber of complexes that transcriptionally regulate genes6,34. We therefore performed chromatin immunoprecipita-
tion followed by quantitative PCR (ChIP qPCR) to determine whether CHD4 binds the RAD51 promoter. We 
found that CHD4 is enriched at the RAD51 promoter when compared with IgG isotype and gene desert controls 
(Fig. 5d). To determine whether CHD4 localization at the RAD51 promoter causes a more permissive chromatin 
environment there, we then performed ChIP for acetylated H3 at lysine 9 (H3K9Ac), an active histone mark, on 
the RAD51 promoter. We found that H3K9Ac levels consequently decreased at the RAD51 promoter after CHD4 
depletion (Fig. 5e) compared to controls, suggesting that CHD4 localization to the RAD51 promoter produces a 
permissive and active chromatin state that in turn may promote expression of RAD51.
Discussion
A longstanding challenge in neuro-oncology has been resistance to DNA damaging therapies. Our work advances 
the understanding of the factors that promote this resistance, and points to one possible strategy to enhance cell 
death. We show that CHD4 expression correlates with poor patient outcomes, and is a specific vulnerability in 
brain tumour cells. King and colleagues recently demonstrated that RAD51 expression contributes to resistance 
of GBM cells to radiation31. Here, we demonstrate that CHD4 drives this increased expression.
Figure 4. Expression of an shCHD4#1 resistant CHD4 construct partially rescues cell viability and increased 
γH2Ax caused by CHD4 suppression. (a) Immunoblot for endogenous CHD4 and overexpressed v5-tagged 
shRNA-resistant CHD4 (CHD4RES) or wild type (CHD4WT), and γH2Ax in LN229 cells. Full-length blots are 
presented in Supplementary Fig. 3. (b) Brightfield images of indicated cells. (c) Cell number (percent relative 
to shCTRL) after expression of shCTRL or shCHD4 #2 in LN229, CHD4RES, and CHD4 cells. (LN229 shCHD4 
#2 vs. CHD4RES shCHD4 #2, p = 0.0374; CHD4RES shCHD4 #2 vs. CHD4 shCHD4 #2, p = 0.0118). (d) Annexin 
V and PI labelling of the indicated cells after expression of shCTRL and shCHD4 #2. (e) Quantification of the 
Annexin V positive cells from (e). (LN229 shCHD4 #2 vs. CHD4RES shCHD4 #2, p < 0.0001; CHD4RES shCHD4 
#2 vs. CHD4 shCHD4 #2, p < 0.0001). Data in (d,f) is shown as mean ± SEM; *p ≤ 0.05; ***p ≤ 0.0001. 
Full-length blots are presented in Supplementary Fig. 3. Data in (c,e) is shown as mean ± SEM; *p ≤ 0.05; 
***p ≤ 0.0001. All data is representative of two independent experiments (with three technical replicates each).
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Figure 5. CHD4 suppression results in decreased HR efficiency, and decreased RAD51 protein, mRNA, and 
promoter activity. (a) Homologous recombination (HR) activity assay for LN229 cells expressing shCTRL 
or shCHD4#1 (p = 0.0023). Data is representative of three independent experiments with three technical 
replicates. (b) Immunoblots for CHD4 and RAD51 in LN229 and U251 cells expressing shCTRL, or two 
shRNAs targeting CHD4. Full-length blots are presented in Supplementary Fig. 3. (c) qRT-PCR analysis of 
RAD51 mRNA expression in LN229 and U251 cells expressing shCTRL, or two shRNAs targeting CHD4. All 
values were normalized to tubulin mRNA and are shown as percent expression relative to shCTRL (LN229: 
shCTRL vs. shCHD4 #1, p < 0.0001, shCTRL vs. shCHD4 #2, p < 0.0001; U251: shCTRL vs. shCHD4 #1, 
p = 0.0013, shCTRL vs. shCHD4 #2, p = < 0.0001). (d) ChIP qPCR analysis of CHD4 occupancy at the 
RAD51 promoter or a gene desert (as a control). Data shown as a fold difference compared with IgG, and 
is representative of two independent experiments. (e) ChIP-qPCR analysis of H3K9Ac occupancy at the 
RAD51 promoter or gene desert control after transduction of shCTRL or shCHD4#2. Data is shown as fold 
difference relative to IgG, and is normalized to H3 occupancy on the RAD51 promoter and gene desert, and is 
representative of two independent experiments (with three technical replicates each). Data in (a,c) shown as 
mean ± SEM; *p ≤ 0.05; **p ≤ 0.001; ***p ≤ 0.0001.
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CHD4 is already understood to play a role in some aspects of DNA damage and resistance. CHD4 recruits 
DDR proteins to sites of double strand breaks and mounts a response to DNA damage in solid and hematologic 
cancers8,23,35. In addition, GBM tumour initiating cells, which are highly resistant to DNA damaging agents36,37, 
overexpress RAD5131; we previously showed that CHD4 is required for this cancer stem cell-like state16. Our 
findings are also consistent with recent work by Kitange and colleagues, who demonstrated that NuRD member 
RBBP4 drives RAD51 transcription by interacting with p300/CPB co-activator complex to generate a permissive 
chromatin environment38. Given that CHD4 co-immunoprecipitates with p30020, and p300 presence activates 
RAD51 transcription39, our observations contribute to an emerging model of CHD4 and NuRD working in com-
plex with p300 to drive RAD51 transcription.
Our study suggests that CHD4 is required for the survival of GBM cell lines, and its suppression has only 
minor effects on normal human astrocytes. We hypothesized that CHD4 loss causes cell death because it ren-
ders the cells ineffective in DNA damage repair. We found that even in unstressed conditions, CHD4 depletion 
increased γH2Ax levels. While others have shown that CHD4 loss in other cancer contexts causes a delay in 
DNA damage repair after exposure to DNA damaging agents8,15,19,23,35; it is rarer that its suppression increases 
γH2Ax expression in the absence of exogenous damage. Such changes have only been reported in ovarian and 
breast cancer cell lines with intact BRCA224. We did not observe increased γH2Ax in unstressed non-transformed 
astrocytes after CHD4 suppression, however, others have reported such findings in primary human fibroblasts40. 
Given that CHD4 dynamically moves the position of nucleosomes on DNA, it is possible that the loss of CHD4 
in GBM cells causes global chromatin relaxation. This is the case in AML23, HeLa40 and Ramos41 cells, where 
loss of CHD4 causes increased global H3K9Ac levels, which is indicative of a more relaxed chromatin state. 
This more relaxed chromatin state might thereby provide DNA less protection against environmental DNA 
damage42,43. Interestingly, we found that exposing CHD4-suppressed GBM cells to radiation did not result in a 
further increase in γH2Ax expression atop that seen with CHD4 suppression alone. This suggests that CHD4 
suppression maximally activates γH2Ax in our system. In contrast, exposing CHD4-suppressed GBM tumour 
initiating cells did result in an increase in γH2Ax expression, which was not resolved to endogenous levels after 
24 hours. Clinically, this suggests that pharmacologic methods to suppress CHD4 activity might synergize with 
radiation, and perhaps even enable a reduction in radiation and its associated toxicities. This is consistent with 
other studies that have shown that inhibition of some HR proteins can sensitize GBM cells to radiation31,44,45.
In summary, CHD4 is overexpressed in GBM and associated with worse outcome. In GBM cells, its suppres-
sion enhances DNA damage and decreases RAD51 expression. Therefore, reducing CHD4 activity or level may 
be one way to enhance the effects of radiation and temozolomide. Given the minimal effects in non-transformed 
astrocytes, such a strategy might leverage a therapeutic window. Lastly, since CHD4 loss also causes differentia-
tion of GBM tumour initiating cells16, it may play multiple important roles in GBM pathogenesis and resistance 
to therapy.
Materials and Methods
Cell lines and cell culture. LN229 and U251 cells were maintained in DMEM with high glucose (Gibco, 
cat#11965-092) Supplemented with 10% foetal bovine serum (Sigma, cat#F2442) and 1% penicillin/streptomycin 
(Gibco, cat#15140-122). Normal human astrocytes (NHA) were purchased from Sciencell and maintained in 
Astrocyte Medium Supplemented with 2% foetal bovine serum, 1% astrocyte growth Supplement and 1% peni-
cillin-streptomycin (Sciencell Research Laboratories, cat#1801). 030846, TS667, BT11247 and TS665 patient-de-
rived cell lines were maintained in NBE medium: Neurobasal medium (Gibco) containing N-2 (Gibco) and B-27 
without vitamin A (Gibco) Supplements, EGF (Peprotech), bFGF (Peprotech), L-glutamine (Gibco), and penicil-
lin-streptomycin (Gibco) as described46. All cells were maintained at 37 C in a humidified incubator with 5% CO2.
DNA Constructs. shRNA constructs: Lentiviral shRNA constructs were obtained from The RNAi Consortium 
(TRC) of the Broad Institute48. The following shRNA clones were used: shCTRL is an shRNA targeting LACZ: 
TRCN0000072235, 5′-CCGG-CCGTCATAGCGATAA CGAGTT-CTCGAG-AACTCGTTATCGCTATGAC 
GG- TTTTTG-3′; target sequence: CCGTCATAGCGATAACGAGTT; shCHD4#1: TRCN0000021363, 
5′-CCGG-GCGGGAGTTCAGTACCAATAA -CTCGAG-TTATTG GTACTGAACTCCCGC- TTTTT-3′ target 
sequence: GCGGGAGTTCAGTACCAATAA; shCHD4#2: TRCN0000021361, 5′-CCGG-GCTGCTGAC 
ATCCTATGAATT-CTCGAG-AATTCATAGG ATGTCAGCAGC- TTTTT-3′, target sequence: GCTGCTGACAT 
CCTATGAATT. Overexpression construct: pLX304 was a gift from David Root (Addgene plasmid # 25890)49. 
pDONR221 CHD4 was obtained from the Harvard Plasmid Database (clone ID: HsCD00080095). pLX304 
CHD4 (v5-tagged) plasmid was made by performing a Gateway cloning reaction using LR Clonase II Plus 
enzyme mix (Invitrogen, Cat# 12538-120). shCHD4#2-resistant pLX304 CHD4 plasmid was made by creating 
4 silent mutations in bases within the shCHD4#2 target sequence using the Quickchange mutagenesis kit as per 
manufacturer’s instructions. The following primer sequences were used for mutagenesis sequentially:
SET #1 – F: 5′-GGTGATCAATTCATAGGACGTCAGCAGCACATGGAAT-3′
R: 5′-ATTCCATGTGCTGCTGACGTCCTATGAATTGATCACC-3′
 SET #2 – F: 5′-TGTCAATGGTGATCAATTCATACGACGTTAGTAGCACATG GAATTTCACAGATG-3′; 
R: 5′-CATCTGTGAAATTCCATGTGCTACTAACGTCGT ATGAATTGATCACCATTGACA-3′
 SET #3 – F: 5′-TGTGAAATTCCATGTGCTACTAACGTCGTACGAGCTGATCAC CATTGACATG-3′; R: 
5′-CATGTCAATGGTGATCAGCTCGTACGACGTTAGTAG CACATGGAATTTCACA-3′
 SET #4 – F: 5′-CTTACGAGCTGGATCACCATTGACATGGC-3′; R: 5′-ACGTG AGGAGCACATGGAAT 
TTCACAGATGC-3′.
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Immunoblot. For protein extraction, cells were lysed with RIPA buffer (10 mM Tris-HCl, 1 mM EDTA, 
0.5 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) Supplemented with 1 X 
Complete EDTA-free protease and phosphatase inhibitor (Roche, cat#04693132001). Protein concentration was 
determined using Pierce BCA protein assay kit (Thermo Fisher Scientific, cat#23225). An equal amount of pro-
tein was loaded per lane into SDS-PAGE gels (BOLT 4–12% Bis-Tris gels, cat#NW04120BOX; or NuPage 3–8% 
Tris-Acetate gels, cat#EA0378BOX), followed by transfer onto 0.45 µM nitrocellulose membranes (Amersham, 
10600008). Membranes were blocked with Odyssey blocking buffer (LICOR, cat#927-40000), followed by over-
night incubation with the primary antibody diluted in Odyssey blocking buffer. After washing 3X in PBS, mem-
branes were incubated with secondary infrared antibodies diluted in blocking buffer, washed a further 3X in 
PBS, then imaged using the LICOR Odyssey Infrared Imaging System. Primary antibodies: anti-Actin (goat), 
1:2000, Santa Cruz, cat#sc-1616; anti-Vinculin (Rabbit), 1:2000, Abcam, cat#ab129002; anti-CHD4 (Rabbit), 
1:250, Abcam, cat#ab72418; anti- γH2Ax (Rabbit), 1:1000, Abcam, cat#ab11174; anti-H2AX (Rabbit), 1:250, Cell 
Signaling, cat#2595; anti-V5 (Rabbit), Millipore, cat#AB3792; anti-RAD51 (Rabbit), Cell Signaling, cat#8875. 
Secondary antibodies: IRDye 680 LT (rabbit), 1:10,000, LICOR, cat#926-68073; IRDye 680 (mouse), 1:10,000, 
LICOR, cat#926-68072; IRDye 800 (goat), 1:10,000, LICOR, cat#926-32214.
Cell viability assay. Cells were seeded at a density of 1 × 105 cells per well in a 6-well tissue-culture treated 
plate and transduced overnight with lentiviral shRNAs Supplemented with polybrene (1 µg/mL; Santa Cruz, 
cat#sc-134220). Media was then removed and replaced with fresh media containing puromycin (2 µg/mL, Gold 
Bio, cat#P-600-1). After two days of selection, cells were counted and 1 × 105 cells/well were plated in a 6-well 
plate, in triplicate. Three days later, cells were counted with trypan blue exclusion.
Apoptosis analysis. Apoptosis analysis was performed using the Annexin V-FITC + PI Apoptosis Detection 
Kit (Leinco Technologies, cat#A432). Briefly, cells were transduced with shRNAs, selected with puromycin for 2 
days, and then an equal number of cells were re-plated in triplicate. Three days later, floating cells and adherent 
cells were combined and counted. Cells were re-suspended in 1 X Binding buffer to a concentration of 1 × 106 
cells/mL, and 10 × 105 cells were transferred to FACS tubes (Falcon, cat#352235). 5 µl of Annexin V-FITC and 
5 µl of PI were added per tube, along with single-stain and unstained controls. Cells were incubated in a 37 C 
incubator for 15 mins, and then analysed using flow cytometry (Becton Dickinson FACS Calibur). Data analysis 
was performed using FlowJo version 10.
Cell cycle analysis. LN229 and U251 cells, after shRNA transduction and selection with puromycin, were 
re-plated at a density of 1 × 105 cells per well of a 6-well plate in triplicate. After 3 days, cells were washed with 
PBS, trypsinized and counted. 2 × 105 cells were fixed in 70% ice cold ethanol for at least 30 mins, washed 3 X with 
ice cold PBS, the supernatant removed, and then resuspended in PI staining solution (0.1 mg/mL PI, 0.1% Triton 
X, 2.5 µg/mL RNAse A) and placed in FACS tubes (Falcon, cat#352235). Cells were incubated at 37 C for 15 mins, 
and then analysed using flow cytometry (Becton Dickinson FACS Calibur). Data analysis was performed using 
FlowJo version 10.
Immunofluorescence. 1 × 104 LN229 cells expressing either shCTRL or shCHD4#1 were plated on Falcon 
8-well culture slides (Corning, cat# 354118). Cells were washed 3 X in PBS, followed by a 5-minute incubation 
in PBST (PBS + 0.05% tween) to permeabilise cells. Cells were washed 3 X in PBS, then fixed for 20 mins in 4% 
formalin. After a further 3 X PBS washes, cells were blocked in Odyssey blocking buffer (LICOR, cat#927-40000) 
for 30 mins, then incubated with anti- γH2Ax (Rabbit) antibody, (1:500, Abcam, cat#ab11174) diluted in Odyssey 
blocking buffer for 1 hr. Cells were then incubated with anti-rabbit alexa fluor 568 (1:1000, Invitrogen, cat#A-
11011) for 1 hr, washed 3 X in PBS, then incubated with 1ug/ml DAPI (Invitrogen, cat# D1306) for 10 mins. Slides 
were mounted using Prolong Diamond mounting medium (Invitrogen, cat#P3670) and imaged using a Nikon 
Eclipse 80i microscope.
Radiation treatment. CHD4 protein expression in response to radiation: LN229 cells were exposed to 9 Gy 
radiation and protein was isolated 1 hr, 6 hr, and 24 hrs after treatment. Immunoblots for CHD4 (anti-CHD4 
(Rabbit), 1:250, Abcam, cat#ab72418) and Vinculin (anti-Vinculin (Rabbit), 1:2000, Abcam, cat#ab129002) were 
performed as previously described. CHD4 suppression and cell growth after radiation: shRNA-transduced LN229 
cells were selected with puromycin for two days, counted and re-plated at a density of 1 × 105 cells per well of a 
6-well plate in triplicate. After three days, cells were either left untreated (0 Gy) or irradiated with 3 Gy or 6 Gy. 
Cells were then counted after a further 3 days. γH2Ax expression after CHD4 suppression and radiation treat-
ment: shRNA-transduced LN229 cells were selected with puromycin for two days, counted and re-plated at a 
density of 1 × 105 cells per well of a 6-well plate in triplicate. After three days, cells were either left untreated (0 Gy) 
or irradiated with 10 Gy or 3 Gy. Protein was isolated at 1 hr, 2 hr, 4 hr, 6 hr and 8 hr (for LN229 cells) or 1.5 hr, 3 hr, 
5 hr, 8 hr, 12 hr or 24 hr (for TS667 cells) after exposure to radiation. All radiation experiments were performed 
using an X-RAD 320 biological irradiator (Precision X-ray Inc.).
Homologous Recombination Assay. A homologous recombination assay was performed according to 
the manufacturer’s instructions (Norgen Biotek Corp., cat#35600). Briefly, LN229 cells expressing either shCTRL 
or shCHD4#1 were co-transfected with dl-1 and dl-2 plasmids (or negative and positive control plasmids), and 
total genomic DNA was isolated 48 hours later using the DNeasy mini kit (Qiagen, cat#69504). A qPCR reaction 
was performed using the supplied primers to determine HR efficiency. If HR is perturbed, the dl-1 and dl-2 plas-
mids will not recombine to produce a PCR product; therefore, the amount of PCR product is directly correlated 
with HR efficiency.
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RNA extraction, cDNA synthesis, and quantitative RT-PCR. RNA was extracted using the RNeasy 
mini kit (QIAGEN, cat#74104) with an on-column RNase-free DNase digestion (QIAGEN, cat#79254). cDNA 
synthesis was performed using the Superscript III first-strand synthesis kit (Invitrogen, cat#18080-051). For 
qRT-PCR, 50 ng of cDNA was added to SYBR Power master mix (Applied Biosystems, cat#A25742) and the 
relevant forward and reverse primers. qRT-PCR was performed using CFX96 Real-Time PCR machine (Biorad) 
under the following conditions: pre-heating step for 10 mins at 95 C, then 40 cycles of 95 C for 15 sec and 60 C for 
1 min, and an ended with a melt curve analysis. Results were analysed using the 2−ΔΔct method. Primer sequences: 
RAD51_F: 5′-CAACCCATTTCACGGTTAGAG C-3′; RAD51_R: 5′-TTCTTTGGCGCATAGGCAACA-3′; 
TUBULIN_F: 5′-TGGAC TCTGTTCGCTCAGGT-3′; TUBULIN_R: 5′-TGCCTCCTTCCGTACCACAT-3′.
Chromatin immunoprecipitation (ChIP) and quantitative PCR. 1 × 107 cells were crosslinked by 
adding 1% paraformaldehyde (Electron Microscopy Sciences, cat#15710) to cells in culture media for 10 mins at 
room temperature, while rotating. The reaction was quenched with glycine to a final concentration of 0.125 M, 
for 5 mins. Cells were centrifuged, the supernatant discarded, and washed twice with cold PBS. Cell pellets were 
frozen at −80C until required. For immunoprecipitation, 50 µL of Protein G Dynabeads (Invitrogen, cat#100040) 
were washed 3X in PBS + 0.1% Tween 20, then incubated with 8 µg of the required primary antibodies or isotype 
control for 6 hours at 4 C. Primary antibodies: anti-CHD4 (Rabbit), Abcam, cat#ab72418; anti-H3 (Rabbit), Cell 
Signaling, cat#9649; anti-H3K9Ac (Rabbit), Cell Signaling, cat#4499; anti-IgG (Rabbit), Millipore, cat#12370. 
In parallel, crosslinked cells were then thawed, lysed for 20 mins in SDS lysis buffer (1% SDS, 10 mM EDTA, 
50 mM Tris-HCl), then 400–1000 bp fragments of chromatin were produced by sonication in a water bath son-
icator (4 C, Misonix ultrasound liquid processor) for 13 cycles of 30 sec on, 30 sec off at 65 Amps. Lysates were 
pre-cleared for 1–2 hrs with beads, and 10% of lysate was saved. Antibody-incubated beads were washed 3X, and 
lysate was diluted 1:2 with ChIP dilution buffer (0.01% SDS, 1.1% Triton X, 1.2 mM EDTA, 16.7 mM Tris-HCl, 
167 mM NaCl), then incubated with the beads overnight at 4 C with rotation. Beads were then washed for 3 mins 
in low salt wash buffer (0.1% SDS, 1% Triton X, 2 mM EDTA, 20 mM Tris-HCl, 150 mM NaCl), high salt wash 
buffer (0.1% SDS, 1% Triton X, 2 mM EDTA, 20 mM Tris-HCl, 500 mM NaCl), LiCl wash buffer (0.25 M LiCl, 
1% NP40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl), and twice in TE buffer. DNA-protein com-
plexes were eluted from the beads by adding 125 µl elution buffer (1% SDS, 0.1 M NaHCO3) for 15 mins at room 
temperature twice. Input samples were diluted to 250 µl with ChIP dilution buffer. DNA-protein complexes were 
de-crosslinked by adding 10 µl 5 M NaCl to the samples and incubating at 65 C overnight. For DNA isolation, 
proteinase K solution (1 µl proteinase K, 5 µl 0.5 M EDTA, and 10 µl 1 M Tris-HCl) was added to each sample and 
incubated for 2 hours at 45 C, then purified using a QIAquick PCR purification column (QIAGEN, cat#28106). 
Quantitative PCR was then performed with input and immunoprecipitated DNA using primers directed to the 
RAD51 promoter (F: 5′-CCCCCGGCATAAAGTTTGA-3′; R: 5′-GCTTTCAGAATTCCCGCCA-3′ 38,39), or 
IGX1A gene desert (QIAGEN, cat#GPH100001C(-)01 A) and Power SYBR according to manufacturer’s instruc-
tions, and analysed using a CFX96 Real-Time PCR machine.
Patient data analysis. The Cancer Genome Atlas (TCGA)25 and Rembrandt26 patient data and gene expres-
sion datasets were analysed using GlioVis data portal27. CHD4 mRNA expression data was downloaded from 
GlioVis data portal and graphs and pairwise t-tests with Bonferroni multiple hypothesis correction were per-
formed using Graphpad Prism version 7.0a.
Statistical analysis. ChIP PCR experiments were performed in triplicate two independent times. All other 
observations were made in triplicate in at least three independent experiments. Quantitative data is expressed as 
mean ± SEM. Datasets with two groups were analysed using unpaired t-tests; datasets with three groups were ana-
lysed using one-way ANOVA and post-hoc Tukey test. Survival analysis was performed using the Kaplan-Meier 
method and analysed by log-rank test.
Data Availability
The data that supports the findings of this study will be made available by the corresponding author upon request.
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